U.S. Software Stock News

NasdaqGS:EXPO
NasdaqGS:EXPOProfessional Services

Where Does Exponent Stand After a 41% Slide and Steady 2025 Declines?

Thinking about whether Exponent is a buy, sell, or hold right now? You’re not alone, especially with so much chatter in the market about where expert consulting firms like this one fit into the bigger investing picture. Let’s take a quick look at the numbers: over the past year, Exponent’s stock has dropped over 41%, and it has slid steadily this year as well. In the past week alone, shares moved down 2.7%, and for the past month, the decline was 6.8%. Even zooming out to three and five...
NYSE:TIXT
NYSE:TIXTProfessional Services

Is TELUS International Stock Poised for a Turnaround After 17% Rally This Year?

Trying to decide what to do with TELUS International (Cda) stock? You are not alone. This is one of those names that has people wondering if the tides are finally turning, or if caution is still the right call. After a challenging few years, TELUS International's share price has caught some positive momentum, climbing 12.0% year-to-date and up 17.3% over the past year. But let’s be real. The memory of that steep 82.3% drop over the last three years is hard to ignore for any investor who’s...
NasdaqCM:YDDL
NasdaqCM:YDDLMetals and Mining

One and One Green Technologies (NasdaqCM:YDDL): Evaluating Valuation After IPO Surge and Global Expansion Plans

One and one Green Technologies (NasdaqCM:YDDL) recently completed its widely discussed initial public offering on the Nasdaq. The event drew attention as shares jumped sharply in both premarket and after-hours trading on debut. See our latest analysis for One and one Green Technologies. The early days of trading for One and one Green Technologies have been anything but quiet. Following its Nasdaq debut, the company’s share price surged for a 1-day share price return of 21.03%, propelled by a...
NasdaqCM:ATYR
NasdaqCM:ATYRBiotechs

aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial - Can Its Credibility Recover?

aTyr Pharma recently reported that its Phase 3 trial for efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint, leading to a wave of investor class action lawsuits alleging misleading statements about the drug’s efficacy. There is significant investor scrutiny on the company’s prior disclosures and communications, as legal investigations focus on the statements made during the trial period. We’ll examine how the trial failure and rising legal challenges may impact aTyr...
NYSE:LDI
NYSE:LDIDiversified Financial

loanDepot (LDI): A Closer Look at Valuation After Recent Share Price Momentum

loanDepot (LDI) shares have seen a mild push upwards lately, trading near $3.07 after gaining almost 2% in the past week. Investors may be eyeing recent momentum, even though the stock has experienced a tough month. See our latest analysis for loanDepot. loanDepot has seen a burst of optimism lately, but that comes after a rocky stretch, including a 1-month share price return of -28.1%. Still, the momentum in 2024 is striking, with the share price up more than 57% year-to-date and an...